OrbusNeich reported FY2025 revenue of USD 180.45 million, up 10%, and profit attributable to owners of USD 41.9 million, up 6%. FY2025 core operating profit (non-HKFRS) rose 20% to USD 34.83 million, while basic earnings per share increased 6% to 5.09 US cents. FY2025 gross profit margin was 67.8%, down 2 percentage points, which the company attributed mainly to lower average selling prices in the PRC, lower sales volume in higher-priced Japan, and higher sales volume in lower-priced Indonesia and the U.S. By market, FY2025 revenue increased 16% to USD 60.47 million in APAC and 20% to USD 46.89 million in EMEA, while U.S. revenue rose 37% to USD 21.2 million, driven by accelerated shipments as tariff impacts eased and demand remained strong. OrbusNeich proposed a FY2025 final dividend of HKD 12 cents per share, up 20%, and said it expects revenue growth to accelerate in 2026 excluding currency effects, supported by new product launches, increased third-party product sales, and continued shifts from distributor to direct sales in certain markets.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OrbusNeich Medical Group Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260312-12049383), on March 12, 2026, and is solely responsible for the information contained therein.